Eli Lilly and Company (LLY) on Thursday reported positive topline results from the Phase III TRIUMPH-1 trial evaluating Retatrutide in adults with obesity or overweight, at least one weight-related comorbidity, and without diabetes.
At 80 weeks, all doses of retatrutide met the trial's primary and key secondary endpoints, delivering significant weight loss. Participants receiving the 9 mg and 12 mg doses lost an average of 64.4 pounds, or 25.9%, and 70.3 pounds, or 28.3%, respectively. Patients taking the 4 mg dose lost an average of 47.2 pounds, or 19.0%.
Among participants taking the 12 mg dose, 65.3% achieved a body mass index below 30 at week 80, moving below the obesity threshold. This included 37.5% of patients who entered the trial with class 3 obesity, defined as a BMI of 40 or higher.
In an extension study involving participants with a BMI of at least 35, those continuing treatment with retatrutide 12 mg through 104 weeks lost an average of 85 pounds, or 30.3%.
The drug candidate also demonstrated improvements in several cardiovascular risk factors, including waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure and high-sensitivity C-reactive protein levels.
Lilly shares closed at $1,018.87 on Wednesday, down 0.25%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.